查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553460

局部麻醉劑市場規模、佔有率、趨勢分析報告：按藥物、按應用、按地區、細分市場預測，2024-2030

Local Anesthesia Drugs Market Size, Share & Trends Analysis Report By Drug (Bupivacaine, Ropivacaine, Lidocaine), By Application (Injectable, Surface Anesthetic), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

局部麻醉劑市場成長與趨勢：

2030年，全球局部麻醉劑市場規模預計將達到51.4億美元，預計2024年至2030年複合年成長率為3.6%。

世界各地的外科手術數量不斷增加，包括整容手術、牙科和整形手術，正在推動局部麻醉劑的成長。

需要術後鎮痛的外科手術數量大幅增加，預計這一趨勢將在整個預測期內持續下去。約 65.0% 的外科手術需要術後疼痛管理。這可能會推動對局部麻醉劑的需求。

Bupivacaine、Articaine、Ropivacaine等有效新藥的推出也推動了全球局部麻醉劑市場的成長。新興國家不斷上漲的醫療費用預計將導致印度、中國和巴西等國家的手術數量增加。預計這將有助於該地區的市場成長。

局部麻醉劑市場報告亮點

  • 截至 2016 年，Lidocaine在產品市場上佔據主導地位，因為它被廣泛用作局部麻醉劑和注射麻醉劑。
  • 依應用，市場分為注射麻醉劑和局部麻醉劑。由於局部麻醉劑廣泛應用於各種外科手術，預計在預測期內局部麻醉劑市場將由注射劑市場主導。在預測期內，藥物傳遞系統的進步可能會推動局部麻醉劑市場的發展。
  • 由於該地區進行了大量的外科手術，北美在局部麻醉劑市場上佔有最大的佔有率。
  • 主要參與者包括 Aspen Pharmacare、Fresenius Kabi、諾華、Sagent Pharmaceutical、Pacira Pharmaceutical、Mylan 和 Teva Pharmaceuticals。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章局部麻醉劑市場變數、趨勢、範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 局部麻醉劑市場分析工具
    • 波特的分析
    • PESTEL分析

第4章局部麻醉劑市場：按藥物分類的預測及趨勢分析

  • 細分儀表板
  • 局部麻醉劑市場：2023 年和 2030 年藥物變化分析
  • Bupivacaine
  • Ropivacaine
  • Lidocaine
  • Chloroprocaine
  • Prilocaine
  • Benzocaine
  • 其他

第5章局部麻醉劑市場：按應用估計和趨勢分析

  • 細分儀表板
  • 局部麻醉劑市場：2023 年和 2030 年按應用分類的變化分析
  • 注射
  • 表面麻醉

第6章局部麻醉劑市場：區域估算及趨勢分析

  • 2023 年及 2030 年按地區分類的局部麻醉劑佔有率
  • 北美洲
    • 2018-2030 年北美局部麻醉劑估計與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2018-2030 年歐洲局部麻醉劑估計與預測
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2018-2030 年亞太地區局部麻醉劑估計與預測
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 拉丁美洲局部麻醉劑估計與預測，2018-2030 年
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 中東和非洲局部麻醉劑估計和預測，2018-2030 年
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Johnson &Johnson Services, Inc.
    • Pfizer Inc.
    • AstraZeneca plc.
    • Novartis AG.
    • Teva Pharmaceutical Industries Ltd.
    • GlaxoSmithKline plc
    • Sanofi SA
    • Merck &Co., Inc.
    • Aspen Pharmacare Holdings Limited
    • Mylan NV
簡介目錄
Product Code: GVR-2-68038-086-6

Local Anesthesia Drugs Market Growth & Trends:

The global local anesthesia drugs market size is anticipated to reach USD 5.14 billion in 2030 and is projected to grow at a CAGR of 3.6% from 2024 to 2030. The rising number of surgical procedures across the globe, including cosmetic surgeries, dental procedures, and plastic surgeries, is driving the growth of local anesthetics.

There has been a considerable increase in the number of surgical procedures requiring post-operative pain relief and this trend is expected to continue throughout the forecast period. Roughly, 65.0% of total surgical procedures require post-operative pain management. This is likely to boost the demand for local anesthesia drugs.

The introduction of new and effective drugs such as levobupivacaine, articaine, and ropivacaine is also driving the growth of the local anesthesia drugs market across the globe. Rising healthcare expenditure in developing countries is expected to result in an increase in the number of surgeries performed in countries such as India, China, and Brazil. This is likely to contribute to market growth in the region.

Local Anesthesia Drugs Market Report Highlights:

  • Lidocaine dominated the market by product as of 2016 owing to its extensive use as a topical and injectable anesthetic
  • By application, the market is bifurcated into injectable and surface anesthetic. The injectable segment is expected to dominate the local anesthesia drugs market during the forecast period owing to extensive usage in different surgical procedures. Advancements in drug delivery systems are expected to drive the market for surface anesthetics over the forecast period
  • North America held the largest share in the market for local anesthesia drugs owing to a significant number of surgical procedures performed in the region
  • Some of the key players are Aspen Pharmacare; Fresenius Kabi; Novartis, Inc.; Sagent Pharmaceutical; Pacira Pharmaceutical; Mylan; and Teva Pharmaceuticals.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Local Anesthesia Drugs Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Local Anesthesia Drugs Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Local Anesthesia Drugs Market: Drug Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Local Anesthesia Drugs Market: Drug Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Bupivacaine
    • 4.3.1. Bupivacaine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Ropivacaine
    • 4.4.1. Ropivacaine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Lidocaine
    • 4.5.1. Lidocaine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Chloroprocaine
    • 4.6.1. Chloroprocaine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Prilocaine
    • 4.7.1. Prilocaine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Benzocaine
    • 4.8.1. Benzocaine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Local Anesthesia Drugs Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Local Anesthesia Drugs Market: Application Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Injectable
    • 5.3.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Surface Anesthetic
    • 5.4.1. Surface Anesthetic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Local Anesthesia Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Local Anesthesia Drugs Share, By Region, 2023 & 2030 (USD Million)
  • 6.2. North America
    • 6.2.1. North America Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Canada Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1. Mexico Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. U.K.
      • 6.3.2.1. U.K. Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Germany Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. France Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Italy Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Spain Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Denmark Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1. Sweden Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1. Sweden Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Japan Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. China
      • 6.4.3.1. China Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. India Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. Australia
      • 6.4.5.1. India Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. South Korea
      • 6.4.6.1. South Korea Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Thailand Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Argentina Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Middle East and Africa
    • 6.6.1. Middle East and Africa Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. South Africa Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Saudi Arabia Local Anesthesia Drugs and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. UAE
      • 6.6.4.1. Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1. Kuwait Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. Johnson & Johnson Services, Inc.
      • 7.4.1.1. Participant's Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Recent Developments/ Strategic Initiatives
    • 7.4.2. Pfizer Inc.
      • 7.4.2.1. Participant's Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Recent Developments/ Strategic Initiatives
    • 7.4.3. AstraZeneca plc.
      • 7.4.3.1. Participant's Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Recent Developments/ Strategic Initiatives
    • 7.4.4. Novartis AG.
      • 7.4.4.1. Participant's Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Recent Developments/ Strategic Initiatives
    • 7.4.5. Teva Pharmaceutical Industries Ltd.
      • 7.4.5.1. Participant's Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Recent Developments/ Strategic Initiatives
    • 7.4.6. GlaxoSmithKline plc
      • 7.4.6.1. Participant's Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Recent Developments/ Strategic Initiatives
    • 7.4.7. Sanofi S.A.
      • 7.4.7.1. Participant's Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Recent Developments/ Strategic Initiatives
    • 7.4.8. Merck & Co., Inc.
      • 7.4.8.1. Participant's Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Recent Developments/ Strategic Initiatives
    • 7.4.9. Aspen Pharmacare Holdings Limited
      • 7.4.9.1. Participant's Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Recent Developments/ Strategic Initiatives
    • 7.4.10. Mylan N.V.
      • 7.4.10.1. Participant's Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Recent Developments/ Strategic Initiatives